|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.49 CNY | -0.95% |
|
+2.30% | -6.73% |
| 03-03 | Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials | MT |
| 01-22 | Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95% | MT |
Main competitors
| Dividend Yield (N) | Dividend Yield (N+1) | P/E (N) | Price to Book (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.28% | 0.38% | 34.51x | 3.29x | 8.72x | 26.28x | 30.15x | 5.5B | ||
| 0.51% | 0.58% | 19.62x | 2.33x | 4.52x | 12.82x | 13.91x | 79.5B | ||
| 0.57% | 0.59% | 27.86x | 3.88x | 5.53x | 15.96x | 20.2x | 55.91B | ||
| -.--% | 0.03% | 45.16x | 6.73x | 13.63x | 25.29x | 29.48x | 51.92B | ||
| 2.83% | 3.17% | 36.44x | 2.54x | 3.68x | 10.6x | 12.04x | 49.05B | ||
| -.--% | -.--% | 16.09x | 1.37x | 2.96x | 8.62x | 9.54x | 27.95B | ||
| -.--% | -.--% | -8.06x | 3.29x | 8.82x | -6.56x | -6.38x | 22.1B | ||
| -.--% | -.--% | 14.88x | 2.56x | 2.38x | 7.53x | 7.08x | 18.84B | ||
| -.--% | 0.23% | 74.55x | 7.39x | 8.82x | 88.19x | 81.77x | 18.69B | ||
| -.--% | -.--% | 649.24x | 3.35x | 5.07x | 12.96x | 45.09x | 14.46B | ||
| -.--% | -.--% | -36.06x | -5.88x | 16.63x | -46.35x | -55.17x | 13.84B | ||
| -.--% | -.--% | 14.03x | - | 3.32x | 12.89x | 26.38x | 11.6B | ||
| -.--% | -.--% | -185.43x | 94.56x | 8.05x | 202.05x | -176.56x | 8.16B | ||
| -.--% | -.--% | 32.29x | - | - | - | - | 7.45B | ||
| -.--% | -.--% | -220.63x | - | - | - | - | 7.34B | ||
| 3.8% | 2.77% | 4.9x | 1.91x | 2.07x | 3.08x | 3.13x | 6.99B | ||
| 2.77% | 2.6% | 12.47x | 1.06x | 1.84x | 7.37x | 9.7x | 6.72B | ||
| 1.28% | 1.44% | 20.9x | 1.23x | - | - | - | 6.03B | ||
| Average | 0.67% | 0.66% | 30.71x | 8.64x | 6.40x | 25.38x | 3.36x | 22.89B | |
| Weighted average by Cap. | 0.64% | 0.7% | 38.32x | 5.08x | 6.46x | 18.38x | 13.17x |
- Stock Market
- Equities
- 603087 Stock
- Sector Gan & Lee Pharmaceuticals.
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















